Crinetics Pharmaceuticals (CRNX) Leases (2019 - 2026)

Crinetics Pharmaceuticals has reported Leases for 8 years, with the latest figure at $39.8 million in Q1 2026.

• For the quarter ending Q1 2026, Leases fell 6.8% year-over-year to $39.8 million; the trailing twelve-month figure through Mar 2026 stood at $39.8 million (down 6.8% YoY), and the FY2025 full-year result was $40.5 million, down 6.93% from the prior year.
• Leases for Q1 2026 stood at $39.8 million, down from $40.5 million in the prior quarter.
• The five-year high for Leases was $48.0 million in Q3 2023, with the low at $1.3 million in Q2 2023.
• Average Leases over 5 years is $28.7 million, with a median of $41.1 million recorded in 2025.
• Year-over-year, Leases dropped 26.16% in 2023 and jumped 3492.18% in 2024.
• Tracing CRNX's Leases over 5 years: stood at $1.5 million in 2022, then surged by 3032.5% to $46.5 million in 2023, then slipped by 6.54% to $43.5 million in 2024, then fell by 6.93% to $40.5 million in 2025, then dropped by 1.73% to $39.8 million in 2026.
• The last three Leases figures came in at $39.8 million (Q1 2026), $40.5 million (Q4 2025), and $41.1 million (Q3 2025), per Business Quant data.

Peer Comparison